Sentence examples for extract survival from inspiring English sources

Is it feasible to design a follow-up documentation system in the HIS which is suitable for several oncological diseases and provides a secondary use of data? 2. Is it possible to extract survival information from routine HIS documentation so that physicians can obtain KM-plots in a timely manner?

We extracted survival outcomes as hazard ratios with 95% confidence intervals.

If this last method was used, three independent persons read the curves to reduce inaccuracy in the extracted survival rates.

To identify survival biomarker in PDAC and its potential mechanism related with cancer progression, we initially extracted survival correlated gene by Cox proportional hazards model from microarray dataset.

We then input the extracted survival rates at specific time points into the spreadsheet developed by Tierney et al. to calculate the HR and 95% CI [ 20].

If this kind of method was used, three independent persons read the curves to reduce the inaccuracy in the extracted survival rates.

Reading the survival rates on the graphical representation of the survival curves was performed independently by three of the authors, but this strategy does not eliminate completely inaccuracy in the extracted survival rates.

Although three readers independently read the survival rates on the graphical representation of the survival curves, the strategy could not ensure a complete accuracy in the extracted survival rates.

To estimate a pooled time lag to benefit across trials, we extracted survival curves for the control and intervention groups for each study before combining the survival curves in our meta-analysis to obtain pooled estimates of absolute risk reduction.

Although the method used for extrapolation of HRs and 95 % CIs is widely accepted and we did not identify any major differences in current study (Additional file 13: Figure S8), we could not completely eliminate inaccuracy in the extracted survival rates.

44 Both studies extracted survival information directly from patient-level data in the SATURN (Sequential Tarceva in Unresectable NSCLC) trial, a Phase III clinical trial that compared erlotinib or placebo as first-line maintenance therapy: one was restricted to EGFR-negative patients, and the other was not.